Breast Cancer Coverage from Every Angle

Recent News

Breast Cancer Treatment Outcomes Across Racial Subgroups: Talazoparib Versus Chemotherapy
Androgen Receptor Agonism in Estrogen Receptor–Positive Breast Cancer
Type 2 Diabetes and Recurrence of Breast Cancer in Older Women
Trastuzumab Biosimilar Receives FDA Approval of Multidose Vial
Predicting Residual Breast Cancer After Neoadjuvant Chemotherapy
TAT 2020: Predictive Biomarker for FGFR Inhibitors in Breast Cancer
Digital Breast Tomosynthesis Versus Digital Mammography: Long-Term Outcomes
TAT 2020: TTK Inhibitor Plus Paclitaxel in Advanced HER2-Negative Breast Cancer
ASCO and ACS Issue Guideline Update on Endocrine Receptor Testing in Breast Cancer
MINDACT Trial of Adjuvant Chemotherapy for Early Luminal Breast Cancer: Does Age Matter?
10-Year Follow-up on Anastrozole in Prevention of Breast Cancer
Neratinib Plus Capecitabine Approved by FDA in HER2-Positive Metastatic Breast Cancer
FDA Accepts BLA for Fixed-Dose Combination Therapy for HER2-Positive Breast Cancer
Physical Activity and Quality of Life After Radiation Therapy for Breast Cancer
Estrogen vs Estrogen Plus Progestin Use in Postmenopausal Women
Tucatinib Receives FDA Priority Review in HER2-Positive Breast Cancer
10-Year Findings With Letrozole in Hormone Receptor–Positive Breast Cancer
10-Year Results With Irradiation After Surgery for Early Breast Cancer
CDK4/6 Inhibitor Plus Letrozole for High-Risk Luminal B Breast Cancer
B and T Immune Cells: A Biomarker of Response to Immunotherapy for Breast Cancer?
CMS to Expand Coverage of Next-Generation Sequencing for Breast or Ovarian Cancer
T-DM1 as Monotherapy for Early HER2-Positive Breast Cancer
Proton-Based Radiotherapy After Breast-Conserving Surgery
S-1 Plus Standard Endocrine Therapy After Surgery for Breast Cancer
Palbociclib Plus Endocrine Therapy Versus Chemotherapy: Outcomes in Metastatic Breast Cancer
Predicting Relapse in Early-Stage Breast Cancer Using ‘Liquid Biopsy’
Pertuzumab Plus Standard Treatment in HER2-Positive Early Breast Cancer
KEYNOTE-522 in Triple-Negative Breast Cancer: Pathologic Complete Response Rates With Pembrolizumab
Oral Paclitaxel With P-Glycoprotein Pump Inhibitor in Metastatic Breast Cancer
Using ctDNA to Predict Recurrence of Triple-Negative Breast Cancer
Accelerated Approval Granted by FDA for [Fam]-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer
FDA Grants Breakthrough Therapy Designation to Tucatinib in Advanced HER2-Positive Breast Cancer
SABCS 2019: Margetuximab Versus Trastuzumab in HER2-Positive Metastatic Breast Cancer
SABCS 2019: Novel Antibody-Drug Conjugate in HER2-Positive Metastatic Breast Cancer
SABCS 2019: Tucatinib-Based Therapy for HER2-Positive Metastatic Breast Cancer
FDA Approves Companion Diagnostic for Alpelisib in PIK3CA-Mutated Metastatic Breast Cancer
Potential Role of E-cadherin in Breast Cancer Metastasis
How Does HIV Infection Affect Survival in Patients With Breast Cancer?
Novel Approach to Targeting Metastatic Breast Cancer Through Sonoporation
Updated USPSTF Recommendation on Medication Use to Reduce Breast Cancer Risk
NCRI Conference: Ongoing Study of Blood Test for Early Detection of Breast Cancer
KEYNOTE-119 Trial of Pembrolizumab Versus Chemotherapy for Triple-Negative Breast Cancer
Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer
FDA Grants Priority Review for Trastuzumab Deruxtecan in Metastatic Breast Cancer
FDA Recommends Warnings on Labeling for Breast Implants
ESMO 2019: Adding Veliparib to Chemotherapy for BRCA-Mutated Breast Cancer
ASCO Breakthrough 2019: Genetic Predictors of Breast Cancer Recurrence After Radiation Therapy
ESMO 2019: Survival Benefit Reported With CDK4/6 Inhibitor in Advanced Breast Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.